Expert opinion on therapeutic targets · 2026
Therapeutic activation of the endocannabinoid system for opioid use disorder, chronic pain, and cancer-related pain: a review of current evidence.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dairo Oluseun, Mitchell-Williams Jocelyn A, Zhang Ping
Аннотация
INTRODUCTION: Opioid use disorder (OUD) and chronic pain are major global health challenges. Although opioid therapies provide effective analgesia, long-term use is limited by safety concerns, dependence, and variable efficacy. Modulation of the endocannabinoid system (ECS) has emerged as a potential therapeutic strategy for pain management and opioid-related disorders.
AREAS COVERED: This narrative review summarizes evidence on ECS-targeted interventions for OUD, chronic non-cancer pain, and cancer-related pain. Relevant literature was identified through PubMed using terms related to the ECS, cannabinoid receptors (CB1 and CB2), phytocannabinoids (Δ⁹-tetrahydrocannabinol [THC] and cannabidiol [CBD]), synthetic cannabinoids, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors, and opioid-cannabinoid interactions. Emphasis is placed on interactions between ECS and opioid signaling pathways and findings from preclinical and clinical studies evaluating efficacy and safety.
EXPERT OPINION: This narrative review summarizes evidence on ECS-targeted interventions for OUD, chronic non-cancer pain, and cancer-related pain. Relevant literature was identified through PubMed using terms related to the ECS, cannabinoid receptors (CB1 and CB2), phytocannabinoids (Δ⁹-tetrahydrocannabinol [THC] and cannabidiol [CBD]), synthetic cannabinoids, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors, and opioid-cannabinoid interactions. Emphasis is placed on interactions between ECS and opioid signaling pathways and findings from preclinical and clinical studies evaluating efficacy and safety.
AREAS COVERED: This narrative review summarizes evidence on ECS-targeted interventions for OUD, chronic non-cancer pain, and cancer-related pain. Relevant literature was identified through PubMed using terms related to the ECS, cannabinoid receptors (CB1 and CB2), phytocannabinoids (Δ⁹-tetrahydrocannabinol [THC] and cannabidiol [CBD]), synthetic cannabinoids, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors, and opioid-cannabinoid interactions. Emphasis is placed on interactions between ECS and opioid signaling pathways and findings from preclinical and clinical studies evaluating efficacy and safety.
EXPERT OPINION: This narrative review summarizes evidence on ECS-targeted interventions for OUD, chronic non-cancer pain, and cancer-related pain. Relevant literature was identified through PubMed using terms related to the ECS, cannabinoid receptors (CB1 and CB2), phytocannabinoids (Δ⁹-tetrahydrocannabinol [THC] and cannabidiol [CBD]), synthetic cannabinoids, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors, and opioid-cannabinoid interactions. Emphasis is placed on interactions between ECS and opioid signaling pathways and findings from preclinical and clinical studies evaluating efficacy and safety.